Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Medipolis Business	804.31M	564.93M	569.08M	683.66M	563.50M
Other	1.97B	1.79B	1.41B	1.44B	968.97M
US Property Management Business	184.40M	45.98M	-	-	-
Unallocated Adjustments	-1.81B	-1.64B	-1.45B	-1.05B	-844.70M
Translational Research Business	108.20M	54.16M	13.23M	16.48M	12.86M
CRO Business	31.28B	31.60B	25.91B	24.00B	17.05B
Total	32.52B	32.41B	26.45B	25.09B	17.75B

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Japan	21.08B	21.52B	17.81B	18.52B	-
United States of America	8.52B	6.37B	4.48B	3.84B	-
Others	1.34B	498.21M	393.21M	2.73B	-
Korea	1.59B	4.02B	3.76B	-	-
Total	32.52B	32.41B	26.45B	25.09B	-

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 11, 2026

Data Sources Report a data error